Quick Facts: What is Yutrepia?
- PHA Canada
- Jun 3, 2025
- 1 min read
What it is
Yutrepia is a new drug: an inhaled form of treprostinil, a prostacyclin analogue. It was just approved by the Food and Drug Administration in the USA.
Who it's for
Yutrepia is approved in the USA for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), to improve exercise ability. Originally, it was approved only for PAH patients, but the company then asked for approval for use in PH-ILD patients as well. It's not approved for other types of PH because it dilates blood vessels, which could lead to dangerously low blood pressure in people whose pulmonary hypertension is associated with other heart or lung issues.
What we know
It's designed to be easy to inhale while still reaching deep in the lungs. Inhaling the drug gets it right where it needs to be -- in the lungs -- so more of it stays there and less of it ends up in the rest of the body. Patients in clinical trials in the USA preferred it to another inhaled version of treprostinil (Tyvaso) that's already available. Tyvaso and Yutrepia will be the same price -- about US$25,000 per month.
What we don't know
We don't know whether Liquidia will seek approval for Yutrepia in Canada. This means Yutrepia won't be available in Canada unless and until they seek Health Canada approval. No inhaled or oral prostacyclin analogues have been approved in Canada yet, including Tyvaso.
Thank you for simplifying complex drug information about Yutrepia in such an accessible format. The direct comparison to Tyvaso and clear explanation of its limited eligible patient groups help avoid misinformation. As a Canadian caregiver for someone living with PH, I greatly appreciate the note on its current unavailability here. Could you share what advocacy steps patients can take to encourage faster Canadian approval of this treatment? --glow up
this is a clear and concise summary of yutrepia, a new inhaled treatment for pulmonary hypertension. it's useful to see the distinction between pah and ph-ild approvals explained, along with the reasoning for its limited use. the comparison to tyvaso and the note about its current unavailability in canada provide important context for patients and caregivers following these developments. Image 2
Excellent insights! Investing in web design in Texas is one of the best ways for businesses to build a strong online presence. A modern, responsive, and user-friendly website not only improves customer experience but also helps increase credibility and conversion rates. Thanks for sharing such helpful information!
7p777 showed up in my feed a few times, so I opened it out of curiosity and just poked around the layout. I didn’t sign up or dig into anything deep, but the site was easy to figure out in like a minute. The navigation is right there and doesn’t make you hunt for it, which I appreciate when I’m just casually browsing. What stood out most is how the page is spaced out—stuff is broken into neat sections instead of being jammed together, so it’s simple to skim and move on. I also like that the headings are clear enough that you always know what part you’re looking at without scrolling back up. Overall it feels calm and readable,…
this is a clear summary of yutrepia's approval and intended use. it's helpful to have the distinction between pah and ph-ild explained, as well as the reasoning for its limited approval. the comparison to tyvaso and the cost context are also useful details for patients and caregivers. the note about its current unavailability in canada is important for setting realistic expectations. Traducir Imagen